Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Table 4 Levels of CD3⁺, CD4⁺, and CD8⁺ in each group (mean ± SD)

Group	CD3+ (%)		CD4+ (%)		CD8+ (%)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	53.56 ± 6.23	61.21 ± 6.32	25.87 ± 6.56	46.87 ± 6.76	39.98 ± 5.21	35.65 ± 9.67
Observation (n = 75)	52.45 ± 5.72	64.98 ± 6.56	26.78 ± 6.48	49.78 ± 5.65	41.34 ± 5.45	29.87 ± 9.87
t	1.026	3.194	0.765	2.606	1.391	3.233
P value	0.307	0.002	0.446	0.010	0.167	0.002